Cargando…

Method dependence, observer variability and kidney volumes in radiation dosimetry of (177)Lu-DOTATATE therapy in patients with neuroendocrine tumours

BACKGROUND: Radionuclide therapy can be individualized by performing dosimetry. To determine absorbed organ doses in (177)Lu-DOTATATE therapy, three methods based on activity concentrations are currently in use: the small volume of interest (sVOI) method, and two methods based on large VOIs either o...

Descripción completa

Detalles Bibliográficos
Autores principales: Sandström, Mattias, Ilan, Ezgi, Karlberg, Anna, Johansson, Silvia, Freedman, Nanette, Garske-Román, Ulrike
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer International Publishing 2015
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4883125/
https://www.ncbi.nlm.nih.gov/pubmed/26501825
http://dx.doi.org/10.1186/s40658-015-0127-y
_version_ 1782434218233561088
author Sandström, Mattias
Ilan, Ezgi
Karlberg, Anna
Johansson, Silvia
Freedman, Nanette
Garske-Román, Ulrike
author_facet Sandström, Mattias
Ilan, Ezgi
Karlberg, Anna
Johansson, Silvia
Freedman, Nanette
Garske-Román, Ulrike
author_sort Sandström, Mattias
collection PubMed
description BACKGROUND: Radionuclide therapy can be individualized by performing dosimetry. To determine absorbed organ doses in (177)Lu-DOTATATE therapy, three methods based on activity concentrations are currently in use: the small volume of interest (sVOI) method, and two methods based on large VOIs either on anatomical CT (aVOI) or on thresholds on functional images (tVOI). The main aim of the present work was to validate the sVOI in comparison to the other two methods regarding agreement and time efficiency. Secondary aims were to investigate inter-observer variability for the sVOI and the change of functional organ volumes following therapy. METHODS: Thirty patients diagnosed with neuroendocrine tumours undergoing therapy with (177)Lu-DOTATATE were included. Each patient underwent three SPECT/CT scans at 1, 4 and 7 days after the treatment. Three independent observers calculated absorbed doses to the right and left kidney and the spleen using sVOI and one observer used aVOI. For tVOI, the absorbed doses were calculated based on automatically drawn isocontours around the organs at different thresholds (42, 50, 60 and 70 %). The inter-observer difference between the calculated absorbed doses for sVOI was calculated, and the differences between the three methods were computed. Ratios of organ volumes acquired at days 1, 4 and 7 versus the volume at day 1 were calculated for the tVOI method. RESULTS: The differences in results of the absorbed dose calculations using all the sVOI and tVOI were small (<5 %). Absorbed dose calculations using aVOI differed slightly more from these results but were still below 10 %. The differences between the three dose calculation methods varied between <5 and 10 %. The organ volumes derived from the tVOI were independent of time for the spleen while they decreased with time for the kidneys. The fastest analysis was performed with the sVOI method. CONCLUSIONS: All three dose calculation methods rendered comparable results with small inter-observer differences for sVOI. Unlike the spleen, the functional volume of the kidneys decreased over time during therapy, which suggests that the absorbed dose calculation for the kidneys on activity concentrations should be performed for each time point. The sVOI is the preferred method for calculating absorbed doses in solid organs.
format Online
Article
Text
id pubmed-4883125
institution National Center for Biotechnology Information
language English
publishDate 2015
publisher Springer International Publishing
record_format MEDLINE/PubMed
spelling pubmed-48831252016-06-21 Method dependence, observer variability and kidney volumes in radiation dosimetry of (177)Lu-DOTATATE therapy in patients with neuroendocrine tumours Sandström, Mattias Ilan, Ezgi Karlberg, Anna Johansson, Silvia Freedman, Nanette Garske-Román, Ulrike EJNMMI Phys Original Research BACKGROUND: Radionuclide therapy can be individualized by performing dosimetry. To determine absorbed organ doses in (177)Lu-DOTATATE therapy, three methods based on activity concentrations are currently in use: the small volume of interest (sVOI) method, and two methods based on large VOIs either on anatomical CT (aVOI) or on thresholds on functional images (tVOI). The main aim of the present work was to validate the sVOI in comparison to the other two methods regarding agreement and time efficiency. Secondary aims were to investigate inter-observer variability for the sVOI and the change of functional organ volumes following therapy. METHODS: Thirty patients diagnosed with neuroendocrine tumours undergoing therapy with (177)Lu-DOTATATE were included. Each patient underwent three SPECT/CT scans at 1, 4 and 7 days after the treatment. Three independent observers calculated absorbed doses to the right and left kidney and the spleen using sVOI and one observer used aVOI. For tVOI, the absorbed doses were calculated based on automatically drawn isocontours around the organs at different thresholds (42, 50, 60 and 70 %). The inter-observer difference between the calculated absorbed doses for sVOI was calculated, and the differences between the three methods were computed. Ratios of organ volumes acquired at days 1, 4 and 7 versus the volume at day 1 were calculated for the tVOI method. RESULTS: The differences in results of the absorbed dose calculations using all the sVOI and tVOI were small (<5 %). Absorbed dose calculations using aVOI differed slightly more from these results but were still below 10 %. The differences between the three dose calculation methods varied between <5 and 10 %. The organ volumes derived from the tVOI were independent of time for the spleen while they decreased with time for the kidneys. The fastest analysis was performed with the sVOI method. CONCLUSIONS: All three dose calculation methods rendered comparable results with small inter-observer differences for sVOI. Unlike the spleen, the functional volume of the kidneys decreased over time during therapy, which suggests that the absorbed dose calculation for the kidneys on activity concentrations should be performed for each time point. The sVOI is the preferred method for calculating absorbed doses in solid organs. Springer International Publishing 2015-10-24 /pmc/articles/PMC4883125/ /pubmed/26501825 http://dx.doi.org/10.1186/s40658-015-0127-y Text en © Sandström et al. 2015 Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made.
spellingShingle Original Research
Sandström, Mattias
Ilan, Ezgi
Karlberg, Anna
Johansson, Silvia
Freedman, Nanette
Garske-Román, Ulrike
Method dependence, observer variability and kidney volumes in radiation dosimetry of (177)Lu-DOTATATE therapy in patients with neuroendocrine tumours
title Method dependence, observer variability and kidney volumes in radiation dosimetry of (177)Lu-DOTATATE therapy in patients with neuroendocrine tumours
title_full Method dependence, observer variability and kidney volumes in radiation dosimetry of (177)Lu-DOTATATE therapy in patients with neuroendocrine tumours
title_fullStr Method dependence, observer variability and kidney volumes in radiation dosimetry of (177)Lu-DOTATATE therapy in patients with neuroendocrine tumours
title_full_unstemmed Method dependence, observer variability and kidney volumes in radiation dosimetry of (177)Lu-DOTATATE therapy in patients with neuroendocrine tumours
title_short Method dependence, observer variability and kidney volumes in radiation dosimetry of (177)Lu-DOTATATE therapy in patients with neuroendocrine tumours
title_sort method dependence, observer variability and kidney volumes in radiation dosimetry of (177)lu-dotatate therapy in patients with neuroendocrine tumours
topic Original Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4883125/
https://www.ncbi.nlm.nih.gov/pubmed/26501825
http://dx.doi.org/10.1186/s40658-015-0127-y
work_keys_str_mv AT sandstrommattias methoddependenceobservervariabilityandkidneyvolumesinradiationdosimetryof177ludotatatetherapyinpatientswithneuroendocrinetumours
AT ilanezgi methoddependenceobservervariabilityandkidneyvolumesinradiationdosimetryof177ludotatatetherapyinpatientswithneuroendocrinetumours
AT karlberganna methoddependenceobservervariabilityandkidneyvolumesinradiationdosimetryof177ludotatatetherapyinpatientswithneuroendocrinetumours
AT johanssonsilvia methoddependenceobservervariabilityandkidneyvolumesinradiationdosimetryof177ludotatatetherapyinpatientswithneuroendocrinetumours
AT freedmannanette methoddependenceobservervariabilityandkidneyvolumesinradiationdosimetryof177ludotatatetherapyinpatientswithneuroendocrinetumours
AT garskeromanulrike methoddependenceobservervariabilityandkidneyvolumesinradiationdosimetryof177ludotatatetherapyinpatientswithneuroendocrinetumours